Charles Schwab
OPRX icon

Charles Schwab’s OptimizeRx OPRX Stock Holding History

Charles Schwab’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-82,072
Closed -$515K – 3522
2026
Q1 		$515K Buy
82,072
+754
+0.9% +$7K ﹤0.01% 3094
2025
Q4 		$997K Buy
81,318
+6,191
+8% +$101K ﹤0.01% 2929
2025
Q3 		$1.54M Buy
75,127
+23,615
+46% +$375K ﹤0.01% 2815
2025
Q2 		$695K Sell
51,512
-2,716
-5% -$29.7K ﹤0.01% 3021
2025
Q1 		$470K Buy
54,228
+12,676
+31% +$77.5K ﹤0.01% 3099
2024
Q4 		$202K Sell
41,552
-6,885
-14% -$38.5K ﹤0.01% 3327
2024
Q3 		$374K Hold
48,437
– – ﹤0.01% 3239
2024
Q2 		$484K Buy
48,437
+5,406
+13% +$59.4K ﹤0.01% 3206
2024
Q1 		$523K Sell
43,031
-1,872
-4% -$27.1K ﹤0.01% 3012
2023
Q4 		$643K Hold
44,903
– – ﹤0.01% 2983
2023
Q3 		$349K Hold
44,903
– – ﹤0.01% 3181
2023
Q2 		$642K Sell
44,903
-6
-0% -$85 ﹤0.01% 2932
2023
Q1 		$657K Sell
44,909
-2,147
-5% -$35.9K ﹤0.01% 2867
2022
Q4 		$791K Sell
47,056
-898
-2% -$15.5K ﹤0.01% 2858
2022
Q3 		$712K Buy
47,954
+1,606
+3% +$31.7K ﹤0.01% 2902
2022
Q2 		$1.27M Buy
46,348
+1,245
+3% +$36.9K ﹤0.01% 2707
2022
Q1 		$1.7M Buy
45,103
+1,033
+2% +$45.7K ﹤0.01% 2704
2021
Q4 		$2.74M Buy
44,070
+713
+2% +$54K ﹤0.01% 2595
2021
Q3 		$3.71M Buy
43,357
+3,010
+7% +$189K ﹤0.01% 2510
2021
Q2 		$2.5M Buy
40,347
+730
+2% +$37.1K ﹤0.01% 2633
2021
Q1 		$1.93M Buy
39,617
+3,867
+11% +$187K ﹤0.01% 2676
2020
Q4 		$1.11M Buy
35,750
+2,765
+8% +$67.7K ﹤0.01% 2742
2020
Q3 		$688K Sell
32,985
-1,075
-3% -$18.5K ﹤0.01% 2788
2020
Q2 		$444K Buy
34,060
+2,060
+6% +$22.4K ﹤0.01% 2884
2020
Q1 		$290K Hold
32,000
– – ﹤0.01% 2904
2019
Q4 		$329K Hold
32,000
– – ﹤0.01% 2954
2019
Q3 		$464K Buy
32,000
+4,022
+14% +$62.2K ﹤0.01% 2830
2019
Q2 		$454K Buy
+27,978
New +$378K ﹤0.01% 2853

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Charles Schwab's OPRX Position: Q2 2026 in Review

Charles Schwab sold out of OptimizeRx (OPRX) in Q2 2026, closing a stake of 82,072 shares — an estimated $515K sold.

Charles Schwab first reported a position in OPRX in Q2 2019 and held it in 28 quarters. The position peaked at $3.71M in Q3 2021. 112 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

  • Charles Schwab reported no remaining OptimizeRx position as of Q2 2026 after selling out during the quarter.
  • Charles Schwab sold 82,072 OptimizeRx shares in Q2 2026, an estimated $515K.
  • Charles Schwab first reported a position in OptimizeRx in Q2 2019 and held it in 28 quarters.
  • Charles Schwab's OptimizeRx position peaked at $3.71M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.